Supadopa TR is primarily prescribed for the treatment of Parkinson’s disease, a progressive neurodegenerative disorder characterized by tremors, rigidity, and bradykinesia (slowness of movement). Additionally, it is indicated for post-encephalitic parkinsonism, a condition that may arise as a consequence of viral encephalitis affecting the basal ganglia of the brain. Supadopa TR is also used in cases of parkinsonism induced by exposure to toxins, such as carbon monoxide poisoning or manganese intoxication.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Levodopa serves as a metabolic precursor to dopamine, a neurotransmitter that plays a crucial role in motor function. Since dopamine itself cannot cross the blood-brain barrier (BBB), levodopa is administered as it is capable of entering the brain, where it is then converted into dopamine. The increase in dopamine levels helps in alleviating the motor symptoms associated with Parkinson’s disease.
When levodopa is taken orally, a significant portion of it is prematurely converted to dopamine in peripheral tissues before reaching the brain, reducing its effectiveness. Carbidopa acts as a decarboxylase inhibitor, preventing the breakdown of levodopa in the periphery. This allows more levodopa to reach the brain, increasing its therapeutic effects while minimizing peripheral side effects such as nausea and vomiting.
Treatment of Parkinson
Levodopa Dose in Immediate Release | Equivalent Daily Dose in Supadopa TR | Dosing Schedule |
---|---|---|
400 mg – 549 mg | 855 mg | 3 capsules (95 mg each) TID |
550 mg – 749 mg | 1140 mg | 4 capsules (95 mg each) TID |
750 mg – 949 mg | 1305 mg | 3 capsules (145 mg each) TID |
950 mg – 1249 mg | 1755 mg | 3 capsules (195 mg each) TID |
≥ 1250 mg | 2340 mg or 2205 mg | 3 capsules (245 mg each) TID |
Iron supplements and dopamine D2 receptor antagonists (such as metoclopramide) may reduce the effectiveness of Supadopa TR.
The side effects of Supadopa TR vary depending on the stage of Parkinson’s disease.
The most commonly reported adverse effects (incidence ≥5%) include:
The most frequently reported side effects in advanced Parkinson’s disease patients, when compared to immediate-release carbidopa-levodopa, include:
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.